Loss of transforming growth factor-beta signaling in mammary fibroblasts enhances CCL2 secretion to promote mammary tumor progression through macrophage-dependent and -independent mechanisms.
Whereas the accumulation of fibroblasts and macrophages in breast cancer is a well-documented phenomenon and correlates with metastatic disease, the functional contributions of these stromal cells on breast cancer progression still remain largely unclear. Previous studies have uncovered a potentially important role for CCL2 inflammatory chemokine signaling in regulating metastatic disease through a macrophage-dependent mechanism. In these studies, we demonstrate a significant regulatory mechanism for CCL2 expression in fibroblasts in mediating mammary tumor progression and characterize multiple functions for CCL2 in regulating stromal-epithelial interactions. Targeted ablation of the transforming growth factor-beta (TGF-beta) type 2 receptor in fibroblasts (Tgfbr2(FspKO)) results in a high level of secretion of CCL2, and cografts of Tgfbr2(FspKO) fibroblasts with 4T1 mammary carcinoma cells enhanced tumor progression associated with recruitment of tumor-associated macrophages (TAMs). Antibody neutralization of CCL2 in tumor-bearing mice inhibits primary tumor growth and liver metastases as evidenced by reduced cell proliferation, survival, and TAM recruitment. Both high and low stable expressions of small interfering RNA to CCL2 in Tgfbr2(FspKO) fibroblasts significantly reduce liver metastases without significantly affecting primary tumor growth, cell proliferation, or TAM recruitment. High but not low knockdown of CCL2 enhances tumor cell apoptosis. These data indicate that CCL2 enhances primary tumor growth, survival, and metastases in a dose-dependent manner, through TAM-dependent and -independent mechanisms, with important implications on the potential effects of targeting CCL2 chemokine signaling in the metastatic disease.
Hembruff
Stacey L
SL
Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS, USA.
Jokar
Iman
I
Yang
Li
L
Cheng
Nikki
N
D000818:Animals; D002469:Cell Separation; D018932:Chemokine CCL2 / Q000378:metabolism*; D018920:Coculture Techniques; D018450:Disease Progression; D005260:Female; D005347:Fibroblasts / Q000276:immunology / Q000378:metabolism*; D005434:Flow Cytometry; D055786:Gene Knockout Techniques; D007150:Immunohistochemistry; D008264:Macrophages / Q000378:metabolism; D008321:Mammary Glands, Animal / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008819:Mice, Nude; D009362:Neoplasm Metastasis / Q000276:immunology / Q000473:pathology; D034741:RNA, Small Interfering; D015398:Signal Transduction / Q000502:physiology*; D016212:Transforming Growth Factor beta / Q000378:metabolism*
D018932:Chemokine CCL2; D034741:RNA, Small Interfering; D016212:Transforming Growth Factor beta
Int J Cancer. 2009 Sep 15;125(6):1276-84
19479998
J Virol. 2009 Jan;83(2):522-39
18987138
Sci Signal. 2008 Mar 11;1(10):pe13
18334714
J Biol Chem. 2009 Oct 16;284(42):29087-96
19720836
Cancer Res. 2007 May 15;67(10):4869-77
17495323
Cell. 2005 Dec 16;123(6):985-7
16360028
Science. 2002 Apr 19;296(5567):550-3
11910072
Cytokine. 2008 Oct;44(1):191-200
18790652
J Med Genet. 2004 May;41(5):e59
15121787
Pathol Res Pract. 1998;194(5):335-40
9651946
Clin Cancer Res. 2004 Oct 15;10(20):6789-95
15501955
Trends Cell Biol. 2001 Nov;11(11):S44-51
11684442
J Exp Med. 1997 Nov 17;186(10):1757-62
9362535
Oncogene. 2005 Jul 28;24(32):5053-68
15856015
Blood. 2000 Jul 1;96(1):34-40
10891427
Neoplasia. 2009 Nov;11(11):1235-42
19881959
Neoplasia. 2009 Dec;11(12):1309-17
20019839
Biochem Biophys Res Commun. 2006 Sep 22;348(2):406-12
16884687
Nat Med. 2008 May;14(5):518-27
18438415
Cell. 2006 Jan 27;124(2):263-6
16439202
Cytokine. 1993 May;5(3):264-75
8218939
Crit Rev Oncol Hematol. 2008 Apr;66(1):1-9
17913510
J Neurooncol. 2008 Jan;86(2):153-63
17703277
Trends Pharmacol Sci. 1999 Apr;20(4):151-6
10322500
Cancer Res. 2006 Jan 15;66(2):605-12
16423985
Clin Cancer Res. 2000 Aug;6(8):3282-9
10955814
Cancer Cell. 2004 Oct;6(4):409-21
15488763
Cell Immunol. 2001 Feb 1;207(2):81-8
11243697
Virology. 2003 May 10;309(2):196-202
12758167
J Clin Invest. 1997 Nov 15;100(10):2552-61
9366570
Differentiation. 1998 Jul;63(3):131-40
9697307
Adv Exp Med Biol. 2007;604:67-86
17695721
J Gen Virol. 2003 Sep;84(Pt 9):2389-2400
12917460
Front Biosci. 2008 Jan 01;13:2548-77
17981734
J Exp Med. 1998 Feb 16;187(4):601-8
9463410